Search results
US FDA approves Moderna's RSV vaccine with lower-than-expected efficacy in its label
Reuters· 7 days ago, opens new tab respiratory syncytial virus (RSV) vaccine, the company announced on Friday, giving...
Promising trial data for Moderna-Merck skin cancer vaccine sends stock rising
Quartz· 4 days agoModerna stock jumped nearly 4% on Tuesday after the the company announced positive data from an...
First Human Death From Bird Flu Puts Vaccine Stocks On The Map - Moderna (NASDAQ:MRNA), CureVac...
Benzinga· 1 day agoVaccine stocks have been on the fly ever since a never-before-seen bird flu strain started infecting...
What To Know About Personalized mRNA Cancer Vaccines After Promising Trials From Moderna And Merck
Forbes· 4 days agoCancer vaccines are finally showing promise as Moderna and Merck touted promising data on an...
Moderna (MRNA) Secures FDA Nod for mRNA-Based RSV Vaccine
Zacks via Yahoo Finance· 4 days agoThe RSV vaccine is Moderna???s (MRNA) second FDA-approved product. Once the vaccine secures the...
FDA vaccine advisers vote unanimously in favor of updated Covid-19 shot for fall
KEYT 3 Santa Barbara· 2 days agoThe US Food and Drug Administration’s committee of independent advisers voted unanimously Wednesday...
The FDA Could, Finally, Approve Novavax's Covid Vaccine — Is Novavax Stock A Buy?
Investor's Business Daily· 4 hours agoNovavax will also receive tiered royalties on sales. Sanofi also made a $70 million investment in...
Moderna, Merck say vaccine improved survival in patients with deadly skin cancer
CNBC· 4 days agoModerna and Merck released more positive three-year data Monday on their experimental vaccine, given...
Is Moderna Inc (MRNA) Set to Underperform? Analyzing the Factors
Guru Focus· 6 hours agoLong-established in the Biotechnology industry, Moderna Inc (MRNA, Financial) has enjoyed a stellar reputation. Notably, its diminished rankings in financial strength, growth ...
Is Moderna Stock a Buy Now That It's a 2-Product Company? | The Motley Fool
The Motley Fool· 4 days agoThe shortened trading week that ended on May 31 was a strange one for the vaccine developer Moderna...